Table 1.

Extracellular matrix (ECM)-derived molecules in cancer diagnosis.

Solid Cancer Type	ECM Molecules	Diagnostic Setting	Author (Reference)
Breast cancer (BC)	COL4	BC patients vs. healthy donors	Mazuoni [25]
	C1M, C3M, C4M, and C4M12	BC patients vs. healthy donors	Bager [26]
	COMP, COL11, and COL10	BC patients vs. healthy donors	Giussani [24]
		BC vs. benign breast disease
	Fibronectin	BC patients vs. healthy donors	Moon [27]
		BC vs. benign breast disease
	MMP-9	BC vs. benign breast disease	Golubnitschaja [28]
	α-1-microglobulin/inter-α-trypsin inhibitor light chain precursor, gelsolin, clusterin, and biotinidase	Infiltrating ductal BC vs. other infiltrating histotype	Cohen [29]
	Fibronectin	Triple-negative vs. hormone-positive BC	Cohen [29]
Lung cancer (LC)	COL10 and SPARC	LC patients vs. healthy donors	Andriani [30]
	Osteopontin	LC patients vs. healthy donors	Kerenidi [31]
	C1M, VCIM	LC patients vs. healthy donors	Willumsen [32]
	Tumstatin (COL18A1)	LC patients vs. healthy donors	Nielsen [33]
		LC vs. COPD 1 or idiopathic pulmonary fibrosis
Colorectal cancer (CRC)	MMP-9	CRC patients vs. healthy donors	Wilson [34]; Emara [35]; Biasi [36]; Mroczko [37]
	MMP-9	CRC patients vs. healthy donors	Gimeno-Garcia [38]
		CRC vs. nonadvanced adenomas
	MMP-9 activity	CRC vs. adenomas	Baisi [36]
	TIMP-1	CRC patients vs. healthy donors	Mroczko [37]
		CRC vs. adenomas
	COL6A3	CRC patients vs. healthy donors	Qiao [39]
	COL10	CRC patients vs. healthy donors	Solé [40]
		Adenoma patients vs. healthy donors
	C1M, C3M, and pro-C3	CRC patients vs. healthy donors	Kehlet [7]
	C1M and pro-C3	CRC vs. adenomas	Kehlet [7]
	C1M, C3M, C4M, and pro-C3	Stage IV vs. stage I-II-III CRC	Kehlet [7]
	Endostatin (COL18A1)	Stage I vs. advanced stage CRC	Kantola [22]
		Advanced stage (T3–4) vs. nonadvanced stage (T1–2)
Urological cancer	MMP2, MMP9, TIMP-1, and TIMP-2	Metastatic RCC patients vs. healthy donors	Miyake [41]
(Renal cell carcinoma—RCC; Urinary bladder cancer—UBC)	MMP7 MMP7	Metastatic or node-positive RCC vs. localized RCC Advanced stage vs. nonadvanced stage RCC Node-positive vs. node-negative UBC patients	Niedworok [42] Szarvas [43]
	MMP9 and TIMP-2	UBC patients vs. healthy donors	Ramón de Fata [44]
Pancreatic cancer (PC)	MMP1, MMP3, MMP7, MMP9, MMP10, and MMP12	PC patients vs. healthy donors	Kahlert [45]
	COL4	PC patients vs. healthy donors	Ohlund [46]
	C1M, C3M and C4M	PDAC 2 vs. healthy donors	Willumsen [20]
	MMP7 and connective tissue growth factor	PDAC 2 vs. healthy donors	Resovi [47]
	MMP7, connective tissue growth factor, plasminogen, fibronectin and COL4	PDAC 2 vs. chronic pancreatitis patients
	COL4, endostatin (COL18A1), tenascin C, and osteopontin	PDAC patients vs. healthy donors	Franklin [48]
	COL6A3	PDAC patients vs. healthy donors PDAC vs. benign lesions	Kang [49]

COPD: chronic obstructive pulmonary disease; ² PDAC: pancreatic ductal adenocarcinoma.